Histogen logo 300.jpg
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
August 31, 2021 16:05 ET | Histogen Inc
SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen logo 300.jpg
Histogen and Amerimmune Announce Additional Findings from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
August 16, 2021 08:00 ET | Histogen Inc
Immunological Data Highlights How Caspase Inhibition May Prevent COVID-19 Disease Progression Emricasan Found to Have Statistically Significant Improvements in Clinically Relevant Hematological and...
Histogen logo 300.jpg
Histogen Reports Second Quarter 2021 Earnings and Provides Business Update
August 11, 2021 16:05 ET | Histogen Inc
Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates Initiated Phase 1/2 Study of HST 003 for Cartilage Regeneration in the Knee HST 004...
Histogen logo 300.jpg
Histogen to Present at the Canaccord Genuity 41st Annual Growth Conference
July 29, 2021 16:05 ET | Histogen Inc
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen logo 300.jpg
Histogen to Report Second Quarter 2021 Financial Results on August 11, 2021
July 28, 2021 16:05 ET | Histogen Inc
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen logo 300.jpg
Histogen Announces Initiation of HST 003 Phase 1/2 Trial for Knee Cartilage Regeneration
June 30, 2021 08:00 ET | Histogen Inc
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced the initiation of its Phase 1/2 clinical trial of HST 003 to evaluate the safety and efficacy of human...
Histogen logo 300.jpg
Histogen and Amerimmune Announce Positive Top-Line Study Results from its Phase 1 Study of Emricasan in Mild Symptomatic COVID-19 Patients
June 22, 2021 08:00 ET | Histogen Inc
Emricasan Found to be Safe and Well Tolerated with No Serious Adverse Events Patients Completing Treatment with Emricasan had a Complete Resolution of the Symptoms Most Commonly Associated in Mild...
Histogen logo 300.jpg
Histogen Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
June 09, 2021 16:01 ET | Histogen Inc
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen logo 300.jpg
Histogen Announces $6.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
June 07, 2021 16:05 ET | Histogen Inc
SAN DIEGO, June 07, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite...
Histogen logo 300.jpg
Histogen Provides Update on its Development Programs and Pipeline Focus
June 03, 2021 08:00 ET | Histogen Inc
Company to Focus its Regenerative Medicine Technology Platform on Developing Orthopedic Product Candidates HST 003 Trial for Cartilage Regeneration in the Knee Remains On-Track with an Anticipated...